SuperworthPAVmed price to sales ratio PAVM
Market value divided by revenue over the last twelve months, since 2022.
- Today, Oct 23, 2026
- 155×
- 4-year median
- 10.5×
- Against its 4-year history
- 97th
- percentile: 0 is its lowest day, 100 its highest
- 4-year range
- 1.6× to 199×
- Peer median
- 0.9×
PAVmed's price to sales ratio is 155× as of Oct 23, 2026.
That is above its 4-year median of 10.5×, higher than on 97% of days in the last 4 years.
Over that time it ranged from 1.6× in Dec 2024 to 199× in Oct 2026.
The median for 3 medical instruments and supplies stocks of a similar size is 0.9×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 155× | 155× | 199× |
| 2025 | 7.0× | 1.7× | 10.9× |
| 2024 | 1.8× | 1.6× | 21.3× |
| 2023 | 21.9× | 15.7× | 139× |
| 2022 | 79.6× | 79.6× | 165× |
Against its peers
Companies in Medical - Instruments & Supplies nearest PAVmed's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| PAVMPAVmed | 155× |
| NEPHNephros | 1.9× |
| APTAlpha Pro Tech | 0.9× |
| KEQUKewaunee Scientific | 0.3× |
| Peer median | 0.9× |
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on PAVmed
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.